Search results for "Drugs"

showing 10 items of 747 documents

The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion.

2019

1. Preamble : Hypercholesterolemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD) [1]. Increased levels of low density lipoprotein cholesterol (LDL-C) are associated with an increased risk of coronary heart disease (CHD) and many clinical trials have shown that reducing LDL-C levels significantly reduced the CHD and CVD risk [[2], [3], [4], [5]]. Thus LDL-C-lowering is the main approach for the management of cardiovascular disease. Current guidelines suggest LDL-C levels targets based on the individual CV risk; such targets can be achieved by several means, which include both lifestyle changes and pharmacological approaches [6], with statins being the cornerstone …

Gastrointestinal Diseases[SDV]Life Sciences [q-bio]Hypercholesterolemia/Self Medication030204 cardiovascular system & hematologyPharmacology03 medical and health sciencesFood-Drug Interactions0302 clinical medicinePlasma cholesterolBiotransformationDouble-Blind MethodChinese traditionalInternal MedicineRed yeast riceMedicineCytochrome P-450 CYP3AHumansMulticenter Studies as TopicProdrugs030212 general & internal medicineLovastatinMusculoskeletal DiseasesMedicine Chinese TraditionalExpert TestimonyComputingMilieux_MISCELLANEOUSBiotransformationRandomized Controlled Trials as TopicBiological ProductsClinical Trials as TopicMolecular StructureRyanodine receptorbusiness.industryGeneral Medicine3. Good healthCholesterol blood[SDV] Life Sciences [q-bio]CholesterolCardiovascular DiseasesExpert opinionDietary Supplementslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular Medicinebusiness
researchProduct

Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology

2020

Inter-patient molecular heterogeneity is the major declared driver of an expanding variety of anticancer drugs and personalizing their prescriptions. Here, we compared interpatient molecular heterogeneities of tumors and repertoires of drugs or their molecular targets currently in use in clinical oncology. We estimated molecular heterogeneity using genomic (whole exome sequencing) and transcriptomic (RNA sequencing) data for 4890 tumors taken from The Cancer Genome Atlas database. For thirteen major cancer types, we compared heterogeneities at the levels of mutations and gene expression with the repertoires of targeted therapeutics and their molecular targets accepted by the current guideli…

Gene mutationMedical OncologychemotherapyGenomeTranscriptomelcsh:ChemistryDrug Delivery SystemsProstateNeoplasmstumor heterogeneityMedicineCluster AnalysisMolecular Targeted TherapyPathology MolecularPrecision Medicinelcsh:QH301-705.5targeted therapeuticscancer drugsSpectroscopyExome sequencingGeneral MedicineGenomicspersonalized medicineComputer Science ApplicationsDrug repositioningmedicine.anatomical_structureAntineoplastic AgentsComputational biologyCatalysisArticleInorganic Chemistrymolecular diagnosticsGenetic HeterogeneityDrug TherapyExome SequencingHumansPhysical and Theoretical ChemistryMolecular Biologygenomeclinical oncologybusiness.industryOrganic ChemistryMolecular diagnosticsmutationslcsh:Biology (General)lcsh:QD1-999MutationPersonalized medicinebusinesstranscriptomeInternational Journal of Molecular Sciences
researchProduct

Self-organized environment-sensitive inulin–doxorubicin conjugate with a selective cytotoxic effect towards cancer cells

2015

An inulin-based random copolymer bearing high dose doxorubicin (18.45% on a weight basis), INU-EDA-P, C-DOXO, was prepared by coupling doxorubicin with inulin though a citraconylamide bridge used as a pH sensitive spacer. A further conjugation with pentynoic acid via an amidic bond led to the hydrophobization of the copolymer which allows the acquisition of a self-assembling ability at low concentration (0.33 mg mL(-1)) combining both Pi-Pi stacking and London interactions. Drug release studies were carried out at different pH demonstrating a remarkable pH dependency, where the maximum release rate was observed at pH mimicking cancer tissue and lysosomal environments. Besides, by measuring …

General Chemical EngineeringInulinprodrugs inulin pH-sensitive doxorubicinGeneral ChemistryProdrugIn vitrochemistry.chemical_compoundMembranechemistryBiochemistryCancer cellmedicineBiophysicsCopolymerDoxorubicinConjugatemedicine.drugRSC Advances
researchProduct

Rational Design of a Carrier Protein for the Production of Recombinant Toxic Peptides in Escherichia coli

2016

Commercial uses of bioactive peptides require low cost, effective methods for their production. We developed a new carrier protein for high yield production of recombinant peptides in Escherichia coli very well suited for the production of toxic peptides like antimicrobial peptides. GKY20, a short antimicrobial peptide derived from the C-terminus of human thrombin, was fused to the C-terminus of Onconase, a small ribonuclease (104 amino acids), which efficiently drove the peptide into inclusion bodies with very high expression levels (about 200-250 mg/L). After purification of the fusion protein by immobilized metal ion affinity chromatography, peptide was obtained by chemical cleavage in d…

Genetics and Molecular Biology (all)0301 basic medicineProtein ExpressionCarboxylic Acidslcsh:MedicinePeptideMedicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)medicine.disease_causeBiochemistrylaw.inventionlawMedicine and Health SciencesAmino Acidslcsh:ScienceAcetic Acidchemistry.chemical_classificationAntimicrobial Cationic PeptideMultidisciplinaryAntimicrobialsOrganic CompoundsHydrolysisMedicine (all)Chemical ReactionsDrugsRecombinant ProteinRecombinant ProteinsAmino acidChemistryBiochemistryPhysical SciencesRecombinant DNAHumanResearch Article030106 microbiologyAntimicrobial peptidesResearch and Analysis MethodsMicrobiologyRibonuclease03 medical and health sciencesResidue (chemistry)RibonucleasesAffinity chromatographyMicrobial ControlGene Expression and Vector TechniquesEscherichia colimedicineSulfur Containing Amino AcidsHumansCysteineMolecular Biology TechniquesMolecular BiologyEscherichia coliPharmacologyMolecular Biology Assays and Analysis TechniquesBiochemistry Genetics and Molecular Biology (all)lcsh:ROrganic ChemistryFormic AcidChemical CompoundsBiology and Life SciencesProteins030104 developmental biologyAgricultural and Biological Sciences (all)chemistrylcsh:QCarrier ProteinPeptidesCarrier ProteinsAcidsAntimicrobial Cationic PeptidesCysteinePLOS ONE
researchProduct

Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy

2018

Background For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predominantly to chronic and severe patients, as a last resort when other treatments failed. Recently, a broader and earlier use of LAIs, particularly second-generation LAIs, has been emphasized. To date, few studies attempted to frame how this change in prescribing took place in real-world practice. Therefore, this study aimed to describe the clinical features of patients prescribed with LAIs, and to explore possible prescribing differences between first- and second-generations LAIs under ordinary clinical practice in Italy. Methods The STAR Network "Depot" Study is an observational, longitudinal…

Genetics and Molecular Biology (all)MalePediatricsEuropean PeopleBipolar DisorderCross-sectional studyEconomicsEpidemiologymedicine.medical_treatmentassessmentviruseslcsh:MedicineSocial SciencesLongitudinal StudieBiochemistryPrescriptionGeographical locations0302 clinical medicineMathematical and Statistical TechniquesBiochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)immune system diseasesEpidemiologyMedicine and Health Scienceslong-acting intramuscular (LAI) antipsychotics; clinical practice; assessment; second-generation antipsychotic (SGA) LAIsAntipsychoticsEthnicitiesLongitudinal Studieslcsh:ScienceMultidisciplinaryvirus diseasesDrugsMiddle Agedclinical practiceItalian PeopleEuropePrescriptionsItalyPhysical SciencesAripiprazoleFemaleBivariate AnalysisStatistics (Mathematics)medicine.drugHumanResearch ArticleAntipsychotic AgentsEmploymentAdultmedicine.medical_specialtyAdolescentResearch and Analysis Methods03 medical and health sciencesMental Health and PsychiatrymedicineHumansPaliperidoneBipolar disorderEuropean UnionStatistical MethodsAntipsychoticCross-Sectional StudiePharmacologyRisperidoneBiochemistry Genetics and Molecular Biology (all)business.industryMood Disorderslcsh:Rmedicine.disease030227 psychiatryAntipsychotic AgentCross-Sectional StudiesAgricultural and Biological Sciences (all)Labor EconomicsMultivariate AnalysisSchizophreniaObservational studylcsh:QPopulation Groupingslong-acting intramuscular (LAI) antipsychoticsPeople and placesbusiness030217 neurology & neurosurgerysecond-generation antipsychotic (SGA) LAIsMathematicsPLoS ONE
researchProduct

In silico identification and experimental validation of hits active against KPC-2 β-lactamase

2018

Bacterial resistance has become a worldwide concern, particularly after the emergence of resistant strains overproducing carbapenemases. Among these, the KPC-2 carbapenemase represents a significant clinical challenge, being characterized by a broad substrate spectrum that includes aminothiazoleoxime and cephalosporins such as cefotaxime. Moreover, strains harboring KPC-type β-lactamases are often reported as resistant to available β-lactamase inhibitors (clavulanic acid, tazobactam and sulbactam). Therefore, the identification of novel non β-lactam KPC-2 inhibitors is strongly necessary to maintain treatment options. This study explored novel, non-covalent inhibitors active against KPC-2, …

Genetics and Molecular Biology (all)Proteomics0301 basic medicineCefotaximeKlebsiella pneumoniaePathology and Laboratory MedicinePhysical ChemistryBiochemistryKlebsiella PneumoniaeDatabase and Informatics MethodsBiochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)AntibioticsKlebsiellaCatalytic DomainMedicine and Health Sciencespolycyclic compoundsDrug InteractionsCrystallographyMultidisciplinarybiologyAntimicrobialsOrganic CompoundsProteomic DatabasesChemistryPhysicsQRDrugsSulbactamCondensed Matter PhysicsBacterial PathogensChemistryBiochemistryMedical MicrobiologyPhysical SciencesCrystal StructureMedicinePathogensbeta-Lactamase InhibitorsResearch Articlemedicine.drugScienceIn silico030106 microbiologySulfonamideResearch and Analysis MethodsMicrobiologyMeropenemTazobactambeta-Lactamases03 medical and health sciencesBacterial ProteinsMicrobial ControlClavulanic acidmedicineSolid State PhysicsMicrobial PathogensPharmacologyLigand efficiencyChemical BondingBacteriaOrganic ChemistryChemical CompoundsOrganismsBiology and Life SciencesHydrogen Bondingbiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesAmidesBiological Databases030104 developmental biologyAgricultural and Biological Sciences (all)
researchProduct

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

2017

Background Intracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR). We modeled ALT and HCV-RNA kinetics in cirrhotic patients treated with currently-used all-DAA combinations to evaluate their mode of action and cytotoxicity compared with telaprevir (TVR)+PR. Study design Mathematical modeling of ALT and HCV-RNA kinetics was performed in 111 HCV-1 cirrhotic patients, 81 treated with all-DAA regimens and 30 with TVR+PR. Kinetic-models and Cox-analysis were used to assess determinants of ALT-decay and normalization. Results HCV-RNA kinetics was biphasic, reflecting …

Genetics and Molecular Biology (all)SimeprevirMaleHepacivirusHepacivirusPharmacologyBiochemistryStiffness0302 clinical medicineAnimal CellsMedicineAmino Acidslcsh:ScienceAlanineOrganic CompoundsLiver Diseases3. Good healthCirrhosisPhysical SciencesAdministrationInterferon030211 gastroenterology & hepatologyDrug Therapy CombinationCellular TypesOligopeptidesHumanOralMaterials ScienceGastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesDrug TherapyHumansAgedKineticPharmacologyHepaciviruBiochemistry Genetics and Molecular Biology (all)Mathematical Modelinglcsh:RChemical CompoundsBiology and Life SciencesProteinsmedicine.diseasedigestive system diseasesAdministration Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; RNA Viral; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)030104 developmental biologyAgricultural and Biological Sciences (all)chemistryAliphatic Amino Acidslcsh:Q0301 basic medicineSofosbuvirlcsh:MedicineAdministration OralMedicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Viral Nonstructural ProteinsTelaprevirchemistry.chemical_compoundSimeprevirMedicine and Health SciencesViralMultidisciplinarybiologyAntimicrobialsMedicine (all)Simulation and ModelingDrugsAlanine TransaminaseHepatitis CMiddle AgedAntiviralsHepatitis CChemistryTreatment OutcomeLiverCombinationOligopeptideRNA ViralFemaleAnatomymedicine.drugResearch ArticleSettore MED/17 - Malattie InfettiveGeneral Science & TechnologyMaterial PropertiesResearch and Analysis MethodsMicrobial ControlVirologyRibavirinMechanical PropertiesNS5AAntiviral Agentbusiness.industryRibavirinHCV DAA ALTViral Nonstructural ProteinOrganic ChemistryCell Biologybiology.organism_classificationKineticsAlanine transaminaseAdministration Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; RNA Viral; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteinsbiology.proteinHepatocytesRNAInterferonsSofosbuvirbusiness
researchProduct

CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA)

2006

4-Methylthioamphetamine (4-MTA) belongs to a group of new amphetamine derivatives that is usually sold as "ecstasy" or "flatliners" on the illicit drug market. Large interindividual differences in 4-MTA mediated toxicity have been reported in humans. Therefore, we tested whether CYP2D6 or its variant alleles as well as CYP3A4 influence the susceptibility to 4-MTA. For this purpose, we used the colony formation assay with Chinese hamster lung fibroblast V79 cells expressing human wild-type CYP2D6 (CYP2D6*1), the low activity alleles CYP2D6*2, CYP2D6*9, as well as human CYP3A4. The obtained results showed that the expression of wild type CYP2D6*1 clearly enhanced the susceptibility to the cyt…

GenotypeCYP3A4Cell SurvivalAmphetaminesWild typePharmacologyBiologyToxicologybiology.organism_classificationIsozymedigestive systemChinese hamsterCell LineDesigner DrugsCricetulusCytochrome P-450 CYP2D6Cell cultureCricetinaeToxicityGenotypeAnimalsCytochrome P-450 CYP3ACytotoxic T cellskin and connective tissue diseasesToxicology
researchProduct

Interventions to Slow Aging in Humans: Are We Ready?

2015

The workshop entitled 'Interventions to Slow Aging in Humans: Are We Ready?' was held in Erice, Italy, on October 8-13, 2013, to bring together leading experts in the biology and genetics of aging and obtain a consensus related to the discovery and development of safe interventions to slow aging and increase healthy lifespan in humans. There was consensus that there is sufficient evidence that aging interventions will delay and prevent disease onset for many chronic conditions of adult and old age. Essential pathways have been identified, and behavioral, dietary, and pharmacologic approaches have emerged. Although many gene targets and drugs were discussed and there was not complete consens…

GerontologyAgingDisease onsetPrescription DrugsLongevityPsychological interventionReviewsBiologyAMP-Activated Protein KinasesGrowth hormoneAging; Anti-aging; Centenarians; Dietary restriction; Lifespan studies; Longevity gene; Longevity regulation; Cell Biology; AgingDietary interventionsBiological FactorsMicelongevity geneSettore BIO/13 - Biologia ApplicataAnimalsHumansSirtuinsProtein restrictionCentenarianInsulin-Like Growth Factor ILifespan studieCaloric RestrictionSettore MED/04 - Patologia GeneraleGeroscienceGene targetsRibosomal Protein S6 KinasesTOR Serine-Threonine Kinasesanti-agingdietary restrictionCell Biologydietary restriction ; lifespan studies ; longevity gene ; centenarians ; anti-aging ; longevity regulation ; aginglongevity regulation3. Good healthDietEnzyme ActivationGene Expression RegulationGrowth HormoneGenetics of agingcentenariansaging; anti-aging; centenarians; dietary restriction; lifespan studies; longevity gene; longevity regulationSignal Transductionlifespan studies
researchProduct

Drug Use Control Perception and Strategies in General and Clinical Population in a Spanish City

2021

Background: This article evaluates the perception of drug use control and strategies in Valencia City (Spain) in a general and clinical population, in two independent studies. Material and Methods: 1071 people participated. In the Study 1 (n= 924) the entire sample came from general population (GP), and in the Study 2 (n=147), 68 were drug users being treated in an Addictive Behaviors Unit (ABU), and 79 people of the GP. The drug use control perception and strategies in both subgroups were compared. The participants filled in the Drug Use Strategies Scale and a Drug Use Survey. Results: A high level of perception of drug control in GP was obtained (72,7% in the Study 1 and 67,5% in the Stud…

GerontologyDrugSubstance-Related DisordersHealth Toxicology and Mutagenesismedia_common.quotation_subjectControl (management)Populationperception of controlling drug useSample (statistics)Articledrugsgeneral_psychologyDrug UsersDrug controlPerceptionmedicineHumanseducationmedia_commoneducation.field_of_studybusiness.industryPublic Health Environmental and Occupational HealthRdrug use control strategiesAbstinencemedicine.diseaserisk and harm reduction approachPharmaceutical PreparationsScale (social sciences)Drug and Narcotic ControlMedicinePerceptionDroguesPsychologyAddictive behaviorbusinessmoderate drug useClinical psychologyInternational Journal of Environmental Research and Public Health
researchProduct